

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

SAMSUNG BIOEPIS CO., LTD.,
Petitioner

v.

REGENERON PHARMACEUTICALS, INC.,
Patent Owner

Case IPR2023-00442
Patent No. 10,130,681 B2

PATENT OWNER'S UPDATED EXHIBIT LIST

TABLE OF EXHIBITS

Ex. No.	Description
2001	Exhibit Number Unused
2002	Curriculum Vitae of Dr. Diana Do
2003-2020	Exhibit Numbers Unused
2021	Transcript of Deposition of Thomas Albini, M.D. (January 20, 2022) (“Albini-Jan-2022”)
2022-2023	Exhibit Number Unused
2024	U.S. Publication No. 2007/0190058 A1 (“Shams”)
2025	Drugs@FDA, Macugen Label, 12/2004, available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/021756lbl.pdf
2026-2031	Exhibit Numbers Unused
2032	Press Release, <i>Regeneron, Regeneron Reports Fourth Quarter and Full Year 2012 Financial and Operating Results</i> , dated February 14, 2013
2033	Press Release, <i>Regeneron, Regeneron Reports Fourth Quarter and Full Year 2019 Financial and Operating Results</i> , dated February 6, 2020
2034	FiercePharma, <i>The Top 20 Drugs by Worldwide sales in 2020</i> (May 3, 2021), available at https://www.fiercepharma.com/special-report/top-20-drugs-by-2020-sales
2035	CDER, Statistical Review for Application Number 125387 (November 18, 2011)
2036	Exhibit Number Unused
2037	Regeneron, ATU Sales Share Data: Wet AMD, c. 2021
2038	Regeneron, ATU Sales Share Data: DME, c. 2021
2039	Regeneron, Eylea Marketing Material, 11/2013
2040	Regeneron, Earnings Call Transcript, 2/13/2012
2041-2049	Exhibit Number Unused
2050	Declaration of Abigail Struthers
2051	Exhibit Number Unused
2052	Declaration of Jeremy Cobb
2053	Declaration of Victoria Reines

2054	Declaration of Matthew M. Wilk
2055	Expert Declaration of David M. Brown, M.D.
2056	Expert Declaration of Dr. Diana V. Do, M.D.
2057	Expert Declaration of Dr. Alexander M. Klibanov, Ph.D.
2058	Expert Declaration of Richard Manning, Ph.D.
2059	Expert Declaration of Richard Manning, Ph.D. from IPR2021-00881- CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2060	Curriculum Vitae of Dr. David Mark Brown, M.D.
2061	Curriculum Vitae of Dr. Alexander M. Klibanov, Ph.D.
2062	Excerpts from SHORTER OXFORD ENGLISH DICTIONARY VOL. 1 (6 th ed. 2007)
2063	Eylea [®] Prescribing Information (Revised 05/2019)
2064	Eylea [®] Approval Letter (November 18, 2011)
2065	Excerpts from the textbook by J.M. Berg et al., BIOCHEMISTRY (5th Edn., Freeman, New York, 2002)
2066	Chapter 27 from W.H. Brown et al., in ORGANIC CHEMISTRY (4th Edn.) (2005)
2067	Hirokawa et al., <i>Tau Proteins: The Molecular Structure and Mode of Binding on Microtubules</i> , 107 J. CELL BIOL. 1449 (1988)
2068	Prangé et al., <i>Exploring Hydrophobic Sites in Proteins with Xenon or Krypton</i> , 30 PROTEINS: STRUCTURE, FUNCTION, AND GENETICS 61 (1998)
2069	Mihailescu et al., <i>A Signature of the T → R Transition in Human Hemoglobin</i> , 98 PROC. NATL. ACAD. SCI. USA 3773 (2001)
2070	Beek et al., <i>The Molecular Structure of Spider Dragline Silk: Folding and Orientation of the Protein Backbone</i> , 99 PROC. NATL. ACAD. SCI. USA 10266 (2002)
2071	Handgraaf et al., <i>Molecular Dynamics Study of Onset of Water Gelation around the Collagen Triple Helix</i> , 64 PROTEINS 711 (2006)
2072	Yu et al., <i>Relationship of Protein Molecular Structure to Metabolisable Proteins in Different Types of Dried Distillers Grains with Solubles: a Novel Approach</i> , 104 BRITISH JOURNAL OF NUTRITION 1429 (2010)
2073	Scott et al., <i>The Folding of Spectrin Domains I: Wild-type Domains Have the Same Stability but Very Different Kinetic Properties</i> , 344 J. MOL. BIOL. 195 (2004)
2074	Kleiger et al., <i>The 1.7 Å Crystal Structure of BOI: A Study of How Two Dissimilar Amino Acid Sequences Can Adopt the Same Fold</i> , 299 J. MOL. BIOL. 1019 (2000)

2075	Demarest et al., <i>Optimization of the Antibody C_H3 Domain by Residue Frequency Analysis of IgG Sequences</i> , 335 J. MOL. BIOL. 41 (2004)
2076	Cantu et al., <i>Thioesterases: A New Perspective Based on Their Primary and Tertiary Structures</i> , 19 PROTEIN SCIENCE 1281 (2010)
2077	Excerpts from the textbook by J.M. Berg et al., BIOCHEMISTRY (6th ed., Freeman, New York, 2006)
2078	Davis-Smyth et al., <i>The Second Immunoglobulin-like Domain of the VEGF Tyrosine Kinase Receptor Flt-1 Determines Ligand Binding and May Initiate a Signal Transduction Cascade</i> , 15 EMBO JOURNAL 4919 (1996)
2079	P17948 VGFR1_Human, available at https://www.uniprot.org/uniprotkb/P17948/entry
2080	P17948 VGFR1_Human, Entry Version 140 (txt) (Jan. 11, 2011), available at https://rest.uniprot.org/unisave/P17948?format=txt&versions=140
2081	Wiesmann et al., <i>Crystal Structure at 1.7 Å Resolution of VEGF in Complex with Domain 2 of the Flt-1 Receptor</i> , 91 CELL 695 (1997)
2082	Lu et al., <i>Identification of the Residues in the Extracellular Region of KDR Important for Interaction with Vascular Endothelial Growth Factor and Neutralizing Anti-KDR Antibodies</i> , 275 J. BIOL. CHEM. 14321 (2004)
2083	Franklin et al., <i>The Structural Basis for the Function of Two Anti-VEGF Receptor 2 Antibodies</i> , 19 STRUCTURE 1097 (2011)
2084	P35968 VGFR2_Human, available at https://www.uniprot.org/uniprotkb/P35968/entry
2085	P35968 VGFR2_Human, Entry Version 127 (txt) (Jan. 11, 2011), available at https://rest.uniprot.org/unisave/P35968?format=txt&versions=127
2086	Bowie et al., <i>Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions</i> , 247 SCIENCE 1306 (1990)
2087	U.S. Patent Application Publication No. 2006/0058234 A1
2088	Iacono et al., <i>Antivascular Endothelial Growth Factor in Diabetic Retinopathy</i> , 46 DEV. OPHTHALMOL. 39 (2010)
2089	Stewart et al., <i>Predicted Biological Activity of Intravitreal VEGF Trap</i> , 92 BR. J. OPHTHALMOL. 667 (2008)
2090	Do et al., <i>An Exploratory Study of the Safety, Tolerability and Bioactivity of a Single Intravitreal Injection of Vascular Endothelial Growth Factor Trap-Eye in Patients with Diabetic Macular Oedema</i> , 93 BR. J. OPHTHALMOL. 144 (2009)

2091	Moroney et al., <i>Aflibercept in Epithelial Ovarian Carcinoma</i> , 5 FUTURE ONCOL. 591 (2009)
2092	U.S. Patent Publication 2010/0160233 A1 to Bissery et al. published on June 24, 2010
2093	Hachiya et al., <i>Increase in Respiratory Cost at High Growth Temperature Is Attributed to High Protein Turnover Cost in Petunia x hybrida Petals</i> , 30 PLANT, CELL, AND ENVIRONMENT 1269 (2007)
2094	Piques et al., <i>Ribosome and Transcript Copy Numbers, Polysome Occupancy and Enzyme Dynamics in Arabidopsis</i> , 5 MOLECULAR SYSTEMS BIOL. 314 (2009)
2095	International Publication No. WO/00/75319
2096– 2101	Exhibit Numbers Unused
2102	Wells, John A., et al. (2015), "Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema," The New England Journal of Medicine 372(13): 1193–1203
2103	Regeneron Research Collaboration Agreement Template (May 5, 2004) – CONFIDENTIAL MATERIAL, SUBJECT TO PROTECTIVE ORDER
2104	Email chain regarding H. E's Marmoset Pregnancy Study – CONFIDENTIAL MATERIAL, SUBJECT TO PROTECTIVE ORDER
2105	Exhibit Number Unused
2106	Macugen Approval Letter (December 17, 2004)
2107	Macugen label submitted with NDA 21-756
2108	David Brown et al., <i>Ranibizumab Versus Verteporfin for Neovascular Age-Related Macular Degeneration</i> , 355 N. ENGL. J. MED. 1432 (2006)
2109	Philip Rosenfeld et al., <i>Ranibizumab for Neovascular Age-Related Macular Degeneration</i> , 355 N. ENGL. J. MED. 1419 (2006)
2110	Press Release, <i>Genentech, Inc. Submits Biologics License Application For FDA Review Of Lucentis(TM) In Wet Age-Related Macular Degeneration</i> (Dec. 30, 2005), available at https://www.biospace.com/article/releases/genentech-inc-submitsbiologics-license-application-for-fda-review-of-lucentis-tm-in-wetage-related-macular-degeneration-/
2111	Genentech News Release, <i>FDA Approves Lucentis for the Treatment of Wet Age-Related Macular Degeneration</i> , (June 30, 2006)

2112	A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RISE), NCT00473330, ClinicalTrials.gov (December 22, 2021), https://www.clinicaltrials.gov/ct2/show/NCT00473330
2113	A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RIDE), NCT00473382 ClinicalTrials.gov (December 22, 2021), https://clinicaltrials.gov/ct2/show/NCT00473382
2114	A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRAVO), NCT00486018 (December 22, 2021), https://clinicaltrials.gov/ct2/show/NCT00486018
2115	A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion (CRUISE), NCT00485836 (December 22, 2021), https://clinicaltrials.gov/ct2/show/NCT00485836
2116	Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO), NCT00943072 (December 22, 2021), https://clinicaltrials.gov/ct2/show/NCT00943072
2117	Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO) (GALILEO), NCT01012973 (December 22, 2021), https://clinicaltrials.gov/ct2/show/NCT01012973
2118	Non-Inferiority Clinical Trials to Establish Effectiveness, Guidance for Industry, November 2016
2119	Eylea (aflibercept) Injection label, revised May 2016
2120	<i>Clinical Approach to Uveitis</i> , in 9 AM. ACAD. OPHTHALMOLOGY, INTRAOCULAR INFLAMMATION AND UVEITIS 101 (2008-2009).
2121	Jaffe et al., <i>Differential Response to Anti-VEGF Regimens in Age-Related Macular Degeneration Patients with Early Persistent Retinal Fluid</i> , 123 OPHTHALMOLOGY 1856 (2016)
2122-2125	Exhibit Numbers Unused
2126	BenEzra et al., “Uveitis in Children and Adolescents,” Br. J. Ophthalmol. 2005; 89:444-448
2127	Exhibit Number Unused

2128	Anthony P. Adamis, <i>Ocular Angiogenesis: Vascular Endothelial Growth Factor and Other Factors</i> , in <i>Retinal Pharmacotherapy</i> 23 (Quan Dong Nguyen et al. eds., 2010)
2129	David M. Brown et al., <i>Ranibizumab Versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study</i> , 116 <i>Ophthalmology</i> 57 (2009)
2130	E.S. Gragoudas et al., <i>Pegaptanib for Neovascular Age-Related Macular Degeneration</i> , 351 <i>N Engl J Med</i> 2805-16 (2004)
2131	Carl D. Regillo, David M. Brown et al., <i>Randomized, Double-masked, Sham-controlled Trial of Ranibizumab for Neovascular Age-related Macular Degeneration: PIER Study Year 1</i> , 145 <i>AM. J. OPHTHALMOLOGY</i> 239 (2008)
2132	Jonathan P. Levine et al., <i>Macular Hemorrhage in Neovascular Age-Related Macular Degeneration After Stabilization with Antiangiogenic Therapy</i> , 29 <i>RETINA</i> 1074 (2009)
2133	Exhibit Number Unused
2134	Regeneron, Earnings Call Transcript, 4/26/2012
2135	Regeneron, Earnings Call Transcript, 7/25/2012
2136	Regeneron, Eylea Marketing Material, c. 2013
2137	Exhibit Number Unused
2138	Regeneron, “Physician ATU: Wave 2,” 2/2013 - CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2139	Regeneron, “For the Treatment of Wet Age-Related Macular Degeneration,” c. 2012
2140	Regeneron, “Physician ATU: Wave 5,” 11/2013 - CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2141	American Academy of Ophthalmology Website, Anti-VEGF Treatments, https://www.aao.org/eye-health/drugs/anti-vegf-treatments (accessed 11/8/2021)
2142	American Academy of Ophthalmology, “Bevacizumab,” 11/2/2021, https://eyewiki.aao.org/Bevacizumab
2143	American Academy of Ophthalmology, “Ophthalmology Subspecialists,” 6/6/2016, https://www.aao.org/eye-health/tips-prevention/ophthalmology-subspecialists
2144	American Academy of Ophthalmology Website, Retinal Vasculitis, https://eyewiki.aao.org/Retinal Vasculitis (accessed 1/13/2022)
2145	American Academy of Ophthalmology Website, What is Avastin, https://www.aao.org/eye-health/drugs/avastin (accessed 11/9/2021)

2146	American Academy of Ophthalmology Website, What is Eylea, https://www.aao.org/eye-health/drugs/what-is-eylea (accessed 11/9/2021)
2147	American Academy of Ophthalmology Website, What is Lucentis, https://www.aao.org/eye-health/drugs/lucentis (accessed 11/9/2021)
2148	American Society of Retina Specialists Website, About Us. https://www.asrs.org/about (accessed 12/6/2021)
2149	American Society of Retina Specialists Website, Age-Related Macular Degeneration, https://www.asrs.org/patients/retinal-diseases/2/agerelated-macular-degeneration (accessed 12/30/2021)
2150	American Society of Retina Specialists Website, Branch Retinal Vein Occlusion, https://www.asrs.org/patients/retinal-diseases/24/branch-retinal-vein-occlusion (accessed 12/30/2021)
2151	American Society of Retina Specialists Website, Central Retinal Vein Occlusion, https://www.asrs.org/patients/retinal-diseases/22/central-retinal-vein-occlusion (accessed 12/30/2021)
2152	American Society of Retina Specialists Website, Diabetic Retinopathy, https://www.asrs.org/patients/retinal-diseases/3/diabetic-retinopathy (accessed 12/30/2021)
2153	Amgen Website, Fusion Protein, https://www.amgen.com/stories/2018/08/the-shape-of-drugs-to-come/fusion-protein (accessed 1/7/2022)
2154	American Speech-Language-Hearing Association Website, Calculating Medicare Fee Schedule Rates, https://www.asha.org/practice/reimbursement/medicare/calculating-medicare-fee-schedule-rates/ (accessed 11/22/2021)
2155	U.S. Department of Health and Human Services (ASPE), “Medicare Part B Reimbursement of Prescription Drugs,” 6/2014, available at: https://aspe.hhs.gov/sites/default/files/private/pdf/106966/ib_mprpd.pdf
2156	Drugs@FDA, Avastin Label, c. 2004, https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/1250851bl.pdf
2157	BasePair Biotechnologies Website, What is an Aptamer? – Aptamers and SELEX, https://www.basepairbio.com/what-is-an-aptamer/ (accessed 12/30/2021)
2158	Bausch and Lomb Website, Visudyne, https://www.bauschretinarx.com/visudyne/ecp/about/ (accessed 12/2/2021)

2159	Bausch and Lomb Website, Help Your Patients Obtain Access to Visudyne, https://www.bauschretinarx.com/visudyne/ecp/ordering/ (accessed 1/12/2022)
2160	Bausch Health Companies, Form 10-K, 2020.
2161	Drugs@FDA, Beovu Label, 10/2019, available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761125s000lbl.pdf
2162	Drugs@FDA, Beovu Label, 6/2020, available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761125s004lbl.pdf
2163	Regeneron, "Physician ATU: Wave 4," 8/6/2013 - CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2164	Bright Focus Foundation Website, Age-Related Macular Degeneration: Facts & Figures, https://www.brightfocus.org/macular/article/age-related-macular-facts-figures (accessed 11/5/2021)
2165	USC-Brookings, "Medicare Payment for Physician-Administered (Part B) Drugs: The Interim Final Rule and a Better Way Forward," available at: https://www.brookings.edu/blog/usc-brookings-schaeffer-on-health-policy/2021/02/10/medicare-payment-for-physician-administered-part-b-drugs/
2166	Calculator.net, "Sample Size Calculator," https://www.calculator.net/sample-size-calculator.html?type=2&cl2=95&ss2=200&pc2=50&ps2=3000&x=68&y=18#findci (accessed 1/25/2022)
2167	Centers for Disease Control and Prevention, "Vision Loss: A Public Health Problem," 6/12/2020, https://www.cdc.gov/visionhealth/basic_information/vision_loss.htm
2168	Centers for Medicare & Medicaid Services Website, Medicare Physician & Other Practitioners - by Provider and Service, https://data.cms.gov/provider-summary-by-type-of-service/medicare-physician-other-practitioners/medicare-physician-other-practitioners-by-provider-and-service (accessed 11/19/2021)
2169	Regeneron, "Eylea Sample Disbursement 2013 to 2021," c. 2021 - CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2170	Regeneron, "US Eylea P&L LTD," 12/2021 - CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER

2171	CloudResearch Website, “Determining Sample Size: How Many Survey Participants Do You Need?” https://www.cloudresearch.com/resources/guides/statistical-significance/determine-sample-size/ (accessed 1/25/2022)
2172	Centers for Medicare & Medicare Services Website, 2021 ASP Drug Pricing Files, https://www.cms.gov/medicare/medicare-part-b-drug-average-sales-price/2021-asp-drug-pricing-files (accessed 11/22/2021)
2173	Centers for Medicare & Medicare Services Website, Medicare Part B Drug Average Sales Price, https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice (accessed 12/8/2021)
2174	Centers for Medicare & Medicaid Services Website, Physician Fee Schedule, https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeeSched (accessed 11/22/2021)
2175	CMS.gov Medicare Coverage Database, “Billing and Coding: Aflibercept (Eylea),” 4/22/2021, available at: https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=53387&ver=28&keyword=&keywordType=starts&areaId=all&docType=6,3,5,1,F,P&contractOption=all&hcpcsOption=code&hcpcsStartCode=J0178&hcpcsEndCode=J0178&sortBy=title&bc=1
2176	Regeneron, “Q4 2020 Performance Update Wet AMD, DME, MEfRVO & DR w/out DME,” 1/29/2021 - CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2177	Julie Donohue et al., <i>A Decade of Direct-to-Consumer Advertising of Prescription Drugs</i> , N. ENGL. J. MED. 35(7): 673–681 (2007)
2178	Julie Donohue & Ernst R. Berndt, <i>Effect of Direct-to-Consumer Advertising on Medication Choice: The Case of Antidepressants</i> , Journal of Public Policy & Marketing 23(2): 115–127 (2004)
2179	Juliana L. Dreyfuss et al., <i>Ocular Angiogenesis</i> , Journal of Ophthalmology (2015)
2180	Miller & Zois, LLC, “Novartis Looking to Repurpose its Dangerous Beovu Drug,” 11/28/2020, https://www.drugrecalllawyerblog.com/novartis-repurpose-beovu.html
2181	Drugs.com Website, Eylea FDA Approval History, https://www.drugs.com/history/eylea.html (accessed 11/16/2021)
2182	Niki Elyasi & David Hemmati Houman, <i>Diabetic Macular Edema: Diagnosis and Management</i> , EYENET MAGAZINE, May 2021: 35-37

2183	Eye Care Surgery Center Website, Macular Degeneration, https://www.eyecaresurgerycenterbr.com/diabetes-retina/macular-degeneration/ (accessed 11/18/2021)
2184	EyeGuru.org Website, Intravitreal Injection Standard Dosing Table, https://eyeguru.org/blog/intravitreal-injection-dosing/ (accessed 12/6/2021)
2185	Drugs@FDA, Eylea Label, 11/2011, https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125387lbl.pdf
2186	Drugs@FDA, Eylea Label, 9/2012, available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125387s004lbl.pdf
2187	Drugs@FDA, Eylea Label, 10/2014, available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125387s043lbl.pdf
2188	Drugs@FDA, Eylea Label, 5/2019, available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125387s061lbl.pdf
2189	Drugs@FDA, Eylea Label, 3/2021, available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125387s069lbl.pdf
2190	Eylea Website, Wet AMD: Dosing Flexibility, https://hcp.eylea.us/about/wet-amd-dosing/ (accessed 1/5/2022)
2191	FDA, "Macugen Drug Approval Package Page," 3/23/2005, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-756_Macugen.cfm
2192	FiercePharma, "Beovu, Novartis," 10/25/2021, https://www.fiercepharma.com/special-report/beovu-novartis-top-10-drug-launch-disasters
2193	FiercePharma, "Novartis' Hot New Eye Drug Beovu Tied to Potential Vision Loss: Experts," 2/24/2020, https://www.fiercepharma.com/pharma/retinal-society-flags-serious-side-effect-for-novartis-beovu
2194	FiercePharma, "The Top 20 Drugs by Worldwide sales in 2020," 5/3/2021, https://www.fiercepharma.com/special-report/top-20-drugs-by-2020-sales
2195	FocusVision, "Survey Sample Size: How Much Do I Need?" 4/11/2019, https://www.focusvision.com/blog/survey-sample-size-how-much-do-i-need/

2196	Gagnon, Marc-Andre and Joel Lexchin (2008), “The Cost of Pushing Pills: A New Estimate of Pharmaceutical Promotion Expenditures in the United States,” PLoS Med 5(1): 29–33
2197	Regeneron, “Physician ATU – Benchmark Wave,” 9/15/2011 - CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2198	GEN, “FDA Green-Lights Genentech’s Lucentis for Macular Edema following Retinal Vein Occlusion, 6/23/2010, https://www.genengnews.com/news/fda-green-lights-genentechs-lucentis-for-macular-edema-following-retinal-vein-occlusion/
2199	Genentech Press Release, “FDA Approves Lucentis for the Treatment of Wet Age-Related Macular Degeneration,” 6/30/2006, https://www.roche.com/dam/jcr:4ca7683d-1513-4e46-bd43-23faa0232507/en/irp060703.pdf
2200	Regeneron, “U.S. Eylea Historical Brand P&L,” 5/2021 - CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2201	Guha, Rahul, Jian Li, and Andrea L. Scott (2009), “The Economics of Commercial Success in Pharmaceutical Patent Litigation,” Landslide 1(5)
2202	HCPCS Codes Website, HCPCS Codes, https://hcpcs.codes/ (accessed 1/6/2022)
2203	Healio, “Access to Retina Providers Shows No Geographic Bias in U.S.,” 3/12/2019, available at: https://www.healio.com/news/ophthalmology/20190312/access-to-retina-providers-shows-no-geographic-bias-in-us
2204	Hopkins Medicine Website, Photodynamic Therapy for Age-Related Macular Degeneration, https://www.hopkinsmedicine.org/health/treatment-tests-and-therapies/photodynamic-therapy-for-agerelated-macular-degeneration (accessed 12/1/2021)
2205	Regeneron, “DME Market Assessment,” 8/2014 - CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2206	IQVIA, Form 10-K, 2020
2207	IQVIA Website, Available IQVIA Data, https://www.iqvia.com/insights/the-iqvia-institute/available-iqvia-data (accessed 1/18/2022)

2208	Regeneron, “Eylea MD ATU – Wave 2 Final Questionnaire,” 12/19/2012 - CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2209	Kaiser Family Foundation, “A Snapshot of Sources of Coverage Among Medicare Beneficiaries in 2018,” 3/23/2021, available at: https://www.kff.org/medicare/issue-brief/a-snapshot-of-sources-of-coverage-among-medicare-beneficiaries-in-2018/
2210	Kaiser Family Foundation, “Medicare Advantage in 2021: Enrollment Update and Key Trends,” 6/21/2021, https://www.kff.org/medicare/issue-brief/medicare-advantage-in-2021-enrollment-update-and-key-trends/
2211	Ling, Davina C., et al. (2002), "Deregulating Direct-to-Consumer Marketing of Prescription Drugs: Effects on Prescription and Over-the-Count Product Sales," Journal of Law and Economics 45: 691–723
2212	Drugs@FDA, Lucentis Label, c. 2006, available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/125156lbl.pdf
2213	Drugs@FDA, Lucentis Label, 6/2010, available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/125156s053lbl.pdf
2214	Drugs@FDA, Lucentis Label, 8/2012, available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125156s0069s0076lbl.pdf
2215	Drugs@FDA, Lucentis Label, 4/2017, available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125156s114lbl.pdf
2216	Drugs@FDA, Lucentis Label, 3/2018, available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125156s117lbl.pdf
2217	Exhibit Number Unused
2218	Regeneron, “Eylea (aflibercept) Injection: Components of Reimbursement,” c. 2015 - CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2219	Mankiw, Nicholas Gregory (2009), Principles of Microeconomics, 5th ed., Mason, OH: South-Western Cengage Learning
2220	Manning, Richard, et al. (2015), “Similar Products at Different Prices: Can Biopharmaceutical Companies Segment Markets?” International Journal of the Economics of Business 22(2): 231–243

2221	Mayo Clinic Website, Wet Macular Degeneration, https://www.mayoclinic.org/diseases-conditions/wet-macular-degeneration/diagnosis-treatment/drc-20351113 (accessed 11/11/2021)
2222	Mayo Clinic Website, Wet Macular Degeneration Symptoms and Causes, https://www.mayoclinic.org/diseases-conditions/wet-macular-degeneration/symptoms-causes/syc-20351107 (accessed 11/11/2021)
2223	Medicare Interactive Website, Medicare Part B Covered Services, https://www.medicareinteractive.org/get-answers/medicare-covered-services/medicare-coverage-overview/summary-of-part-b-covered-services (accessed 11/22/2021)
2224	Medicare Interactive Website, The Parts of Medicare (A, B, C, D), https://www.medicareinteractive.org/get-answers/medicare-basics/medicare-coverage-overview/original-medicare (accessed 11/30/2021)
2225	Medicare.gov Website, Macular Degeneration Tests & Treatment, https://www.medicare.gov/coverage/macular-degeneration-tests-treatment (accessed 11/22/2021)
2226	Medicare.gov Website, Medicare Advantage Plans, https://www.medicare.gov/sign-up-change-plans/types-of-medicare-health-plans/medicare-advantage-plans (accessed 12/31/2021)
2227	Medicare Website, When Does Medicare Coverage Start?, https://www.medicare.gov/basics/get-started-with-medicare/sign-up/when-does-medicare-coverage-start (accessed 12/15/2021)
2228	Medline Plus Website, Laser Photocoagulation – Eye, https://medlineplus.gov/ency/article/007664.htm (accessed 12/2/2021)
2229	Regeneron, WAC Pricing File, 5/2021 - CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER [Updated Version - Served Not Filed]
2230	Novartis, Annual Report, 2020
2231	Novartis Press Release, “Novartis Receives FDA Approval for Beovu, Offering Wet AMD Patients Vision Gains and Greater Fluid Reductions vs Aflibercept,” 10/8/2019, https://www.novartis.com/news/media-releases/novartis-receives-fda-approval-beovu-offering-wet-amd-patients-vision-gains-and-greater-fluid-reductions-vs-aflibercept
2232	Novartis Press Release, “US FDA Approves Updated Novartis Beovu® Label, to Include Additional Safety Information,” 6/11/2020, https://www.novartis.com/news/media-releases/us-fda-approves-updated-novartis-beovu-label-include-additional-safety-information

2233	Centers for Medicare & Medicaid Services, October 2012 ASP Pricing File, https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/2012ASPFiles
2234	Centers for Medicare & Medicaid Services, October 2013 ASP Pricing File, https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/2013ASPFiles
2235	Centers for Medicare & Medicaid Services, October 2015 ASP Pricing File, https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/2015ASPFiles
2236	Centers for Medicare & Medicaid Services, October 2016 ASP Pricing File, https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/2016ASPFiles
2237	Centers for Medicare & Medicaid Services, October 2017 ASP Pricing File, https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/2017ASPFiles
2238	Centers for Medicare & Medicaid Services, October 2018 ASP Pricing File, https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/2018ASPFiles
2239	Centers for Medicare & Medicaid Services, October 2019 ASP Pricing File, https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/2019ASPFiles
2240	Centers for Medicare & Medicaid Services, October 2014 ASP Pricing File, https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/2014ASPFiles
2241	Centers for Medicare & Medicaid Services, October 2020 ASP Pricing File, https://www.cms.gov/medicare/medicare-part-b-drug-average-sales-price/2020-asp-drug-pricing-files
2242	Centers for Medicare & Medicaid Services, October 2021 ASP Pricing File, https://www.cms.gov/medicare/medicare-part-b-drug-average-sales-price/2021-asp-drug-pricing-files
2243	American Society of Retina Specialists, “Preferences and Trends (PAT) Survey,” 2016 - CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2244	American Society of Retina Specialists, “Preferences and Trends (PAT) Survey,” 2015 - CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2245	Pindyck, Robert and Daniel Rubinfeld (2013), Microeconomics, Upper Saddle River: Prentice Hall

2246	Regeneron Website, About, https://www.regeneron.com/about (accessed 11/3/2021)
2247	Regeneron Press Release, “Eylea Injection Receives FDA Approval for the Treatment of Diabetic Macular Edema (DME),” 7/29/2014, https://investor.regeneron.com/news-releases/news-release-details/eylear-aflibercept-injection-receives-fda-approval-treatment
2248	Regeneron Press Release, “Eylea Injection Receives FDA Approval for Macular Edema Following Retinal Vein Occlusion (RVO),” 10/6/2014, https://investor.regeneron.com/news-releases/news-release-details/eylear-aflibercept-injection-receives-fda-approval-macular-edema
2249	Regeneron Press Release, “FDA Approves Eylea Injection for Diabetic Retinopathy, 5/13/2019, https://investor.regeneron.com/news-releases/news-release-details/fda-approves-eylear-aflibercept-injection-diabetic-retinopathy
2250	American Society of Retina Specialists, “Preferences and Trends (PAT) Survey,” 2014 - CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2251	Regeneron Website, History, https://www.regeneron.com/about/history (accessed 12/15/2021)
2252	Regeneron Press Release, “Regeneron Announces FDA Approval of Eylea® (Aflibercept) Injection for Macular Edema Following Central Retinal Vein Occlusion,” 9/21/2012, https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-fda-approval-eylear-aflibercept-injection
2253	Regeneron Website, Research Areas, https://www.regeneron.com/science/research-areas (accessed 11/3/2021)
2254	Regeneron, Form 10-K, 2020
2255	Retinal Physician, “Revisiting an Early Treatment for Wet AMD: Is There a Role for Thermal Laser in the Era of Anti-VEGF Therapy?” 9/1/2011, https://www.retinalphysician.com/issues/2011/september-2011/revisiting-an-early-treatment-for-wet-amd
2256	Roche, Finance Report, 2020
2257	Roche Press Release, “FDA Approves Lucentis for Treatment of Diabetic Macular Edema,” 8/13/2012, https://www.roche.com/investors/updates/inv-update-2012-08-13.htm

2258	Roche Press Release, “FDA Approves Roche’s Lucentis for Diabetic Retinopathy, the Leading Cause of Blindness Among Working Age Adults in the United States, 4/18/2017, https://www.roche.com/media/releases/med-cor-2017-04-18b.htm
2259	American Society of Retina Specialists, “Preferences and Trends Membership Survey,” 2009 - CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2260	Schweitzer, Stuart (2007), Pharmaceutical Economics and Policy: Second Edition, New York: Oxford University Press
2261	ScienceDaily, “FDA Approves First Angiogenesis Inhibitor to Treat Colorectal Cancer,” 2/27/2004, https://www.sciencedaily.com/releases/2004/02/040227071334.htm
2262	Sivaprasad, Sobha (2021), “Sustained-Release Steroid Options For DME Therapy,” Retina Today (0921): 34–36
2263	Regeneron, Eylea Sales Summary, c.2020 - CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2264	Verywell Health Website, Macular Degeneration: Timeline of Vision Loss Progression, 3/21/2021, https://www.verywellhealth.com/macular-degeneration-timeline-5069947
2265	Vestrum Health Website, Homepage, https://www.vestrumhealth.com/index.php (accessed 1/3/2022)
2266	Vestrum Health Website, Pharmaceutical Companies, https://www.vestrumhealth.com/pharma.php (accessed 1/3/2022)
2267	Drugs@FDA, Visudyne Label, 4/2016, at 3, available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021119s027lbl.pdf
2268	Weidner, Susan, et al. (2021), “Observations Regarding the Average Sales Price Reimbursement Methodology,” Evidence-Based Oncology 27(4): 156–160
2269	World Health Organization, “Blindness and Vision Impairment Fact Sheet,” 10/14/2021, available at: https://www.who.int/news-room/fact-sheets/detail/blindness-and-visual-impairment
2270	Yahoo Finance, “Beovu Now Publicly Reimbursed in Ontario and New Brunswick for the Treatment of Neovascular Wet AMD,” 12/17/2021, https://finance.yahoo.com/news/beovu-brolucizumab-injection-now-publicly-120000109.html
2271	Yorston, David (2014), “Anti-VEGF Drugs in the Prevention of Blindness,” Community Eye Health Journal 27(87): 1-3

2272	Regeneron, “Eylea Q2 2021 Performance,” 8/2/2021 - CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2273	Vestrum, Anti-VEGF Category Sales Shares, c. 2/2022 - CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2274	Regeneron, “Eylea Wet AMD Line of Therapy Insights,” 4/2020 - CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2275	Regeneron, “Vestrum Anti-VEGF Market Share Adjustment Overview,” 5/10/2019 - CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2276	Regeneron, “Eylea Q2 2020 Performance (Vestrum Projection Data),” 8/4/2020 - CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2277	Regeneron, “Marketing Planning Process,” 9/2011 - CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2278	Regeneron, “Wave 1 2021 Performance Update Wet AMD, DME, MEfRVO, and DR w/out DME,” 9/2021 - CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2279	Regeneron, ATU Sales Share Data: All Indications, c. 2021
2280-2281	Exhibit Numbers Unused
2282	Regeneron, ATU Sales Share Data: CRVO, c. 2021
2283	Regeneron, ATU Sales Share Data: BRVO, c. 2021
2284	Regeneron, ATU Sales Share Data: DR w/o DME, c. 2021
2285	Regeneron, Eylea Gross & Net Sales P&L YTD, c.2021 - CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2286	Prema Abraham et al., <i>Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-Related Macular Degeneration: PIER Study Year 2</i> , 150 AM. J. OPHTHALMOLOGY 315 (2010)
2287	Irene Barbazetto et al., <i>Dosing Regimen and the Frequency of Macular Hemorrhages in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab</i> , 30 RETINA 1376 (2010)

2288	Daniele Cruz, <i>PIER Data Suggest a Need for Tailored Injection Schedule</i> , Ocular Surgery News, (Sept. 1, 2006), https://www.healio.com/news/ophthalmology/20120331/pier-data-suggest-a-need-for-tailored-injection-schedule
2289	<i>Retinal Physician Symposium Covers Broad Range of Topics</i> , Retinal Physician (Sept. 1, 2006), https://www.retinalphysician.com/issues/2006/september-2006/retinal-physician-symposium-covers-broad-range-of .
2290	CDER Approved Labeling for BLA Application 125156 (Lucentis®) (2006)
2291	Ursula Schmidt-Erfurth et al., <i>Efficacy and Safety of Monthly Versus Quarterly Ranibizumab Treatment in Neovascular Age-related Macular Degeneration: The EXCITE Study</i> , 118 OPTHALMOLOGY 831 (2011)
2292	David S. Boyer, David M. Brown et al., <i>A Phase IIIb Study to Evaluate the Safety of Ranibizumab in Subjects with Neovascular Age-related Macular Degeneration</i> , 116 OPTHALMOLOGY 1731 (2009)
2293	Ron Margolis & K. Bailey Freund, <i>Hemorrhagic Recurrence of Neovascular Age-Related Macular Degeneration Not Predicted by Spectral Domain Optical Coherence Tomography</i> , 4 Retinal Cases & Brief Rep. 1 (2010)
2294	Young Gun Park et al., <i>New Approach of Anti-VEGF Agents for Age-related Macular Degeneration</i> , J. OPTHALMOLOGY (2012)
2295	Richard Spaide, <i>Ranibizumab According to Need: A Treatment for Age-related Macular Degeneration</i> , 143 Am. J. Ophthalmology 679 (2007)
2296	David M. Brown et al., <i>Primary Endpoint Results of a Phase II Study of Vascular Endothelial Growth Factor Trap-Eye in Wet Age-related Macular Degeneration</i> , 118 Ophthalmology 1089 (2011)
2297	Jeff Heier, David M. Brown et al., <i>The 1-year Results of CLEAR-IT 2, a Phase 2 Study of Vascular Endothelial Growth Factor Trap-Eye Dosed As-needed After 12-week Fixed Dosing</i> , 118 Ophthalmology 1099 (2011)
2298	Clinical Study Agreement Between Vitreoretinal Consultants and Regeneron Pharmaceuticals, Inc. (July 31, 2007) - CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2299	VGFT-OD-0605 (VIEW 1 Trial) Protocol Signature Page - CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2300	EYLEA® Prescribing Information (“Eylea PI”)

2301	Press Release, <i>Regeneron Announces FDA Approval of Eylea® (Aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration</i> (Nov. 18, 2011)
2302	Eylea® Approval Letter (November 18, 2011)
2303	Bhisitkul, Robert B. and Stewart, Jay M., <i>Alternative anti-VEGF treatment regimens in exudative age-related macular degeneration</i> , Expert Rev. Ophthalmol., Vol. 5, No. 6 (2010)
2304	FDA, <i>22 Case Studies Where Phase 2 and Phase 3 Trials Had Divergent Results</i> (Jan. 2017)
2305	A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (SPECTRI), ClinicalTrials.gov, https://clinicaltrials.gov/ct2/show/NCT02247531
2306	A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (CHROMA), ClinicalTrials.gov, https://clinicaltrials.gov/ct2/show/NCT02247479
2307	Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-1), ClinicalTrials.gov, https://clinicaltrials.gov/ct2/show/NCT03577899
2308	Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-2), ClinicalTrials.gov, https://clinicaltrials.gov/ct2/show/NCT03630952
2309	A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreal Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy, ClinicalTrials.gov, https://clinicaltrials.gov/ct2/show/NCT01944839
2310	A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreal Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy, ClinicalTrials.gov, https://clinicaltrials.gov/ct2/show/NCT01940900
2311	Andrew E. Mathis, <i>Fine-Tuning Your Anti-VEGF Injection Protocols: The Second Article in Our Series Recapping Research and Analysis Presented at Our Annual Meeting</i> , Retinal Physician (Oct. 1, 2009), https://www.retinalphysician.com/issues/2009/october-2009/fine-tuning-your-anti-vegf-injection-protocols

2312	Scott W. Cousins, <i>Controversies in the Long-term Management of Neovascular AMD: The Role of Imaging in Clinical Decision Making</i> , Retinal Physician (Jan. 1, 2010), https://www.retinalphysician.com/issues/2010/jan-feb/controversies-in-the-long-term-management-of-neova
2313	Jerry Helzner, <i>Lucentis After 1 Year: Doctors Praise This Practice-transforming Therapy—But Find Drawbacks</i> , Retinal Physician (July 1, 2007), https://www.retinalphysician.com/issues/2007/july-aug/lucentis-after-1-year
2314	FDA, Guidance for Industry: Expedited Programs for Serious Conditions—Drugs and Biologics (May 2014), https://www.fda.gov/media/86377/download
2315	<i>Macugen for Proliferative Diabetic Retinopathy Study With Extended Dosing (M-PDRS ED)</i> , ClinicalTrials.gov, https://clinicaltrials.gov/ct2/show/NCT0148677
2316	Ron P. Gallemore & David Nguyen, <i>When Anti-VEGF Treatment Fails: Retina Specialists Are Charting New Territory and Learning How to Spot and React to Failed Anti-VEGF Therapy</i> , Rev. Ophthalmology (Mar. 20, 2008)
2317	Press Release, Kanghong Pharmaceutical, <i>Announcement of Chengdu Kanghong Pharmaceutical Group Co., Ltd. on Stopping the Global Multi-center Clinical Trial of Conbercept Ophthalmic Injection</i> , http://epaper.zqrb.cn/html/2021-04/10/content_716426.htm?div=-1 (English translation)
2318	Press Release, Kanghong Pharmaceutical, <i>Announcement of Chengdu Kanghong Pharmaceutical Group Co., Ltd. on Stopping the Global Multi-center Clinical Trial of Conbercept Ophthalmic Injection</i> , http://epaper.zqrb.cn/html/2021-04/10/content_716426.htm?div=-1 (original)
2319	Michael Thomas et al., <i>Comparative Effectiveness of Aflibercept for the Treatment of Patients with Neovascular Age-related Macular Degeneration</i> , 7 Clinical Ophthalmology 495 (2013)
2320	Matthew Ohr & Peter K. Kaiser, <i>Aflibercept in Wet Age-related Macular Degeneration: A Perspective Review</i> , 3 THERAPEUTIC ADVANCES CHRONIC DISEASE 153 (2012)
2321	<i>FDA Approves Eylea for Wet Age-Related Macular Degeneration</i> , Drugs.com, (Nov. 18, 2011), https://www.drugs.com/newdrugs/fda-approves-eylea-wet-age-related-macular-degeneration-2955.html

2322-2331	Exhibit Number Unused
2332	Ophthotech Press Release “Ophthotech Announces Results from Pivotal Phase 3 Trials of Fovista® in Wet Age-Related Macular Degeneration,” December 12, 2016
2333	Genentech Press Release “Genentech Statement on Chroma, the Second Phase III Study for Lampalizumab,” November 9, 2017
2334	Ciulla, TA & Rosenfeld, PJ, <i>Antivascular Endothelial Growth Factor Therapy For Neovascular Ocular Diseases Other than Age-Related Macular Degeneration</i> , Current Opinion in Ophthalmology 2009, 20:166-174
2335-2344	Exhibit Numbers Unused
2345	<i>A Study to Evaluate rhuFab V2 in Subjects With Minimally Classic or Occult Subfoveal Neovascular Macular Degeneration</i> , NCT00056836, ClinicalTrials.gov (Mar. 26, 2003), https://clinicaltrials.gov/ct2/show/NCT00056836
2346	<i>A Study to Compare rhuFab V2 With Verteporfin Photodynamic in Treating Subfoveal Neovascular Macular Degeneration</i> , NCT00061594, ClinicalTrials.gov (Mar. 30, 2003), https://www.clinicaltrials.gov/ct2/show/NCT00061594
2347	CENTER FOR DRUG EVALUATION & RESEARCH, BLA No. 125156, Lucentis Medical Review (“Lucentis MR”)
2348	<i>A Study of rhuFab V2 (Ranibizumab) in Subjects With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)</i> , NCT00090623, ClinicalTrials.gov (Sept. 1, 2004), https://clinicaltrials.gov/ct2/show/NCT00090623
2349	P Mitchell et al., <i>Ranibizumab (Lucentis) in Neovascular Age-Related Macular Degeneration: Evidence from Clinical Trials</i> , 94 BRIT. J. OPHTHALMOLOGY 2 (2009) (date of online publication) (“Mitchell”)
2350	Exhibit Number Unused
2351	Erik Christensen, <i>Methodology of Superiority vs. Equivalence Trials and Non-Inferiority Trials</i> , 46 J. HEPATOLOGY 947 (2007) (“Christensen”)
2352	<i>Ranibizumab Injections to Treat Macular Telangiectasia Without New Blood Vessel Growth</i> , NCT00685854, ClinicalTrials.gov (May 28, 2008), https://clinicaltrials.gov/ct2/show/NCT00685854
2353	CATT Research Group, <i>Ranibizumab and Bevacizumab for Neovascular AMD</i> , 364 N. ENGL. J. MED. 1897 (2011)

2354	Arun Bhatt, <i>Protocol deviation and violation</i> , 3 PERSPECTIVES CLINICAL RESEARCH 117 (2012)
2355	CENTER FOR DRUG EVALUATION & RESEARCH, BLA No. 125-387, Eylea Medical Review (“Eylea MR”)
2356	<i>VEGF Trap-Eye: Investigation of Efficacy and Safety in Wet AMD (VIEW 2)</i> , NCT00637377, ClinicalTrials.gov (Mar. 17, 2008), https://clinicaltrials.gov/ct2/show/NCT00637377 (“NCT-377”)
2357	<i>Samsung Bioepis Co. Ltd. v. Regeneron Pharms., Inc.</i> , IPR2023-00566, Paper 2 (P.T.A.B. Feb. 10, 2023)
2358	<i>Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD) (VIEW1)</i> , NCT00509795, ClinicalTrials.gov (Apr. 28, 2009), https://clinicaltrials.gov/ct2/show/NCT00509795 (“NCT-795”)
2359	<i>Product Development in Biotechnology</i> , in BIOTECHNOLOGY FUNDAMENTALS (Taylor & Francis Group ed., 3d ed. 2000)
2360	Order on Claim Construction, <i>Regeneron Pharms., Inc. v. Mylan Pharms. Inc.</i> , No. 22-cv-00061-TSK (N.D.W. Va. April 19, 2023) (ECF No. 427)
2361	Press Release, <i>Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration</i> (May 8, 2008), http://investor.regeneron.com/releasedetail.cfm?ReleaseID=394065
2362	Jeffery S. Heier, <i>VEGF Trap-Eye for Exudative AMD</i> , RETINAL PHYSICIAN, April 1, 2009
2363	Zhang Ni & Peng Hui, <i>Emerging Pharmacologic Therapies for Wet Age-Related Macular Degeneration</i> , 223 OPHTHALMOLOGICA 401 (2009)
2364	Anne E. Fung et al., <i>An Optical Coherence Tomography-Guided, Variable Dosing Regimen with Intravitreal Ranibizumab (Lucentis) for Neovascular Age-related Macular Degeneration</i> , 143 AM. J. OPHTHALMOLOGY 566 (2007)
2365	Geeta A. Lalwani et al., <i>A Variable Dosing Regimen with Intravitreal Ranibizumab for Neovascular Age-Related Macular Degeneration: Year 2 of the PrONTO Study</i> , 148 AM. J. OPHTHALMOLOGY 43 (2009)
2366	Retina Society, <i>VEGF Trap-Eye in Wet AMD CLEAR-IT 2: Summary of One-Year Key Results, A Phase 2, Randomized, Controlled Dose-and Interval-Ranging Study of Intravitreal VEGF Trap-Eye in Patients With Neovascular, Age-Related Macular Degeneration</i> (Sept. 28, 2008)
2367	Exhibit Number Unused

2368	Brian C. Toy et al., <i>Treatment of Non-Neovascular Idiopathic Macular Telangiectasia Type 2 with Intravitreal Ranibizumab: Results of a Phase II Clinical Trial</i> , 32 RETINA 996 (2012)
2369	U.S. Dep't of Health & Human Services, <i>Approval of Research with Conditions: OHRP Guidance (2010)</i> , available at https://www.hhs.gov/ohrp/regulations-and-policy/guidance/guidance-on-irb-approval-of-research-with-conditions-2010/index.html (Nov. 10, 2010)
2370	VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group, <i>Pegaptanib Sodium for Neovascular Age-Related Macular Degeneration: Two-Year Safety Results of the Two Prospective, Multicenter, Controlled Clinical Trials</i> , 113 OPHTHALMOLOGY 992 (2006)
2371	Kenneth A. Getz et al., <i>Measuring the Incidence, Causes, and Repercussions of Protocol Amendments</i> , 45 DRUG INFORMATION J. 265 (2011)
2372	Marc Buyse, <i>Phase III Design: Principles</i> , 5 CHINESE CLIN. ONCOL. 1 (2013)
2373- 2374	Exhibit Numbers Unused
2375	American Academy of Ophthalmology, <i>What Is Macular Telangiectasia?</i> available at: https://www.aao.org/eye-health/diseases/macular-telangiectasia
2376	“Endophthalmitis,” American Academy of Ophthalmology Basic and Clinical Science Course Section 9; Chapter 9 (2008-2009)
2377	Jorma B. Mueller & Christopher M. McStay, <i>Ocular Infection and Inflammation</i> , 26 EMERGENCY MEDICINE CLINICS N. AM. 57 (2008)
2378	Thomas Albini & Narsing A. Rao, <i>Immunologic Processes in Disease</i> , in PATHOBIOLOGY OF OCULAR DISEASE (Gordon K. Klintworth & Alec Garner, eds., 2008)
2379	Rachel R. Caspi, <i>A Look at Autoimmunity & Inflammation in the Eye</i> , 120 J. CLINICAL INVESTIGATION 3073 (2010)
2380	Bahram Bodaghi, <i>Chronic Severe Uveitis: Etiology and Visual Outcome in 927 Patients from a Single Center</i> , 80 MEDICINE 2063 (2001)
2381	Mayo Clinic, <i>Stye (sty)</i> , Overview, available at: https://www.mayoclinic.org/diseases-conditions/sty/symptoms-causes/syc-20378017

2382	Boston Children's Hospital, <i>Orbital Cellulitis (Periorbital Cellulitis)</i> , available at: https://www.childrenshospital.org/conditions/orbital-cellulitis#:~:text=The%20terms%20orbital%20cellulitis%20and,area%20that%20encloses%20the%20eye
2383	<i>Study Population</i> , in FUNDAMENTALS OF CLINICAL TRIALS (Lawrence M. Friedman et al, eds., 2010)
2384	Transcript of Deposition of Dr. Edward Chaum (October 3, 2023)
2385	U.S. Food & Drug Administration, <i>Step 3: Clinical Research</i> , available at: https://www.fda.gov/patients/drug-development-process/step-3-clinical-research#phases
2386	Excerpts from MERRIAM-WEBSTER'S MEDICAL DESK DICTIONARY (2005)
2387	[Redacted] Memorandum Opinion and Order Following Bench Trial, <i>Regeneron Pharms., Inc. v. Mylan Pharms. Inc.</i> , No. 22-cv-00061-TSK (N.D.W. Va. January 31, 2024) (ECF No. 692)

Dated: February 9, 2024

Respectfully Submitted,

/Deborah E. Fishman/

Deborah E. Fishman (Reg. No. 48,621)

3000 El Camino Real #500

Palo Alto, CA 94304

**Counsel for Patent Owner,
Regeneron Pharmaceuticals, Inc.**

CERTIFICATE OF SERVICE

Pursuant to 37 C.F.R. §§42.6(e)(4)(i) *et seq.*, the undersigned Certifies that on February 9, 2024, a true and entire copy of this **PATENT OWNER'S UPDATED EXHIBIT LIST** was served via e-mail to the Petitioner at the following email addresses:

qe-samsungbioepis@quinnemanuel.com
raynimrod@quinnemanuel.com
matthewtraupman@quinnemanuel.com
elliotchoi@quinnemanuel.com
zachsummers@quinnemanuel.com
sarahcork@quinnemanuel.com
landonsmith@quinnemanuel.com

/Deborah E. Fishman/

Deborah E. Fishman (Reg. No. 48,621)
3000 El Camino Real #500
Palo Alto, CA 94304

**Counsel for Patent Owner,
Regeneron Pharmaceuticals, Inc.**